ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Therapies for Patients With HR-Positive Breast Cancer

Hyman B. Muss, MD
Published Online:5:13 PM, Wed April 23, 2014
Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, gives an overview of therapies for patients with HR-positive breast cancer. Muss discussed this topic in a talk at the 31st Annual Miami Breast Cancer Conference®.

Clinical Pearls

  • Exemestane can extend the time of disease control substantially with some risk of toxicities.
  • Data have shown that biologic agents and traditional endocrine therapy can work together for possibly much better outcomes.
  • Pharmaceutical companies have begun to develop new compounds and analyze models of enhancing endocrine therapy with biologic agents.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.